Enveric Biosciences, Inc. · NASDAQ:ENVB
Enveric Biosciences — Merger or Acquisition (June 2021)
28 slides from Enveric Biosciences's merger presentation, Jun 8, 2021
Slide 1: Enveric Biosciences: Extending & Enhancing Life for Cancer Patients
| ENVERIC B.1 OOS C IEIRGer S EXTENDING & ENHANCING LIFE FOR CANCER PATIENTS < (NASDAQ: ENVB) JUNE 2021 WWW.ENVERIC.COM
Slide 2: Important Information for Investors and Stockholders
Important Information for Investors and Stockholders No Offer or Solicitation This communication is for informational purposes only and is not intended to and does not constitute an offer to sell, or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. It doe
Slide 3: Cautionary Statement Regarding Forward Looking Statements
Cautionary Statement Regarding Forward Looking Statements This communication contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements provide Enveric
Slide 4: Cautionary Statement Regarding Forward Looking Statements
Cautionary Statement Regarding Forward Looking Statements Important risk factors could cause actual future results and other future events to differ materially from those currently estimated by management, including, but not limited to, the risks that: a condition to the closing of the proposed tran
Slide 5: Company Overview
Company Overview Strong Financial Base cae + Projected to have 18 Months of Cash on Hand Mission * No Debt Extend + Enhance the Life of + Strong Liquidity Cancer Patients who Live with + Clean Cap Table the Debilitating Side Effects of Cancer Treatment a Intend to Progress our Targeted Clinical Init
Slide 6: Management Team
Management Team DAVE JOHNSON CEO and Chairman Elect oversaw the $4.18 spin out of Convatec from Bristol Myers Squibb; former CEO of Alliqua Biomedical, a developer of wound care technologies (Learn Mor rari CRO BCAA, Ni STELLA VNOOK Chief Technology Officer 25+ years experience transforming and grow
Slide 7: Our Strategy
Our Strategy Develops and/or identifies undervalued, under-researched, naturally occurring compounds; advancing these compounds in partnership with leading clinics; and plans to partner for commercial opportunities. IDENTIFY Identity promising natural compounds that have strong anecdotal evidence an
Slide 8: Key Accomplishments in 2021
Key Accomplishments in 2021 December 31, 2020: February 25, 2021: Started trading on Nasdaq Expanded our partnerships Strong liquidity early + Exclusive agreement with PureForm Global January 15, 2021: Enhanced our balance sheet March 10, 2021: * Raising >$20.0M in capital Expanded our scientific op
Slide 9: Enveric Biosciences and MagicMed Industries
4" ENVERIC Mag¥cMed BIOSCIENCES INDUSTRIES » BUILDING A DISCOVERY & CLINICAL < PLATFORM TO SERVE THE MIND AND BODY (NASDAQ: ENVB) JUNE 2021 WWW.ENVERIC.COM
Slide 10: The Psychedelic Revolution...
The Psychedelic Revolution... A New Vision for Mental Health > 2019 — J&J Drug Approval for Spravato > esketamine for Depression > Johns Hopkins and Yale Publications > “Center for Psychedelic + Consciousness Research” > 100 Publications > NASDAQ Companies 1) Compass Pathways 2) MindMed > Market Cap
Slide 11: Why did ENVB target the Psychedelic Space?
Why did ENVB target the Psychedelic Space? Patient-Centric Company Naturally Occurring Compounds WwW Oncology Related Support Care 4 “Cancer Related Distress” Let’s Heal both the “Mind & Body” WWW.ENVERIC.COM + NASDAQ: ENVB 1
Slide 12: Drug Discovery and Clinical Stage Biotech Emerges
Drug Discovery and Clinical Stage Biotech Emerges d | ENVERIC * BIO EXTENDING & ENHANCING LIFE FOR CANCER PATIENTS 3'4 psychedelic company listed on NASDAQ and 1° with focus on the R&D of cannabinoids and psychedelics Synergistic and complimentary combination of clinical Enveric team and discovery/d
Slide 13: MagicMed Industries
MagicMed Industries Value Drivers ¢ Strong I.P. Portfolio ¢ 15 Patent Applications — Covering 1 Million Molecules ¢ World-Class Discovery & Development « Psychedelic + Cannabinoid Therapies ¢ Molecule Agnostic « Using PsyAl to select best candidates ¢ Developing PTSD Drug for Cancer Related Distress
Slide 14: Investment Highlights
Investment Highlights Builds Upon Strong IP Pipeline — Short, Medium and Long Term * 7 Molecules Builds Development and Clinical Engine * Discovery through Phase III NASDAQ Value Inflection Points + Enveric (ENVB): ~$100MM Market Cap * Compass Pathways (CMPS): ~$1.4B Market Cap * MindMed (MNMD): ~$1
Slide 15: Oncology Supportive Care
Oncology Supportive Ca
Slide 16: Large Unmet Need in Supportive Care
Large Unmet Need in Supportive Care * Cannabinoid derivates can be leveraged across multiple delivery methods in supportive care indications Nausea & Vomiting + Large market potential RadiadernatiGe * Chemotherapy often causes adverse side effects for cancer patients * Developing product candidates
Slide 17: Our Pipeline
Our Pipeline A robust pipeline of novel therapies across several indications, with multiple data points expected in 2021 for radiodermatitis, glioblastoma and chemotherapy-induced neuropathy. Glioblastoma Multiforme (GBM) Radiation Dermatitis (also called Radiodermatitis) Chemotherapy-Induced Periph
Slide 18: Radiation Dermatitis
Radiation Dermatitis CBD AND DERMATITIS... DEMONSTRATED EFFECTS a JB radiation Dermatitis @ EN v ERIC © atiianonoure ror VEN GES — cancerrarenrs WWW.ENVERIC.COM - NASDAQ: ENVB 18
Slide 19: Chemo-Induced Neuropathy
Chemo-Induced Neuropathy CHEMOTHERAPY-INDUCED How Does Cannabis Help with Neuropathy? Reduces pain intensity YF PERIPHERAL NEUROPATHY Anti-inflammatory Relief Relaxes muscles STATS We CAN HELP € RECOVERY CENTERS" WWW.ENVERIC.COM + NASDAQ: ENVB 19
Slide 20: Glioblastoma
Glioblastoma I PREVALENCE + 22,000 Adults in the US diagnosed each ye + 15,000 Resulted in Death : SSIMGHEIE oie + 2 —3/100,000 Incidence Rate + GBM Occurs in 17% of all Brain Cai CURRENT + Surgery / Radiotherapy STANDARD + Temozolomide (TMZ) + Bevacizumab OF CARE QUALITY Median survival 10- OF LIFE
Slide 21: PureForm — Expanding Our Partnerships
PureForm — Expanding Our Partnerships Supply & Development + Launched development collaboration and exclusive supply agreement to support cannabinoid clinical programs + Aimed to treat pain and inflammation resulting from cancer treatments initially targeting —i supportive care indications that incl
Slide 22: Diverse Biotech — Expanding Our Scientific Options
Diverse Biotech — Expanding Our Scientific Options Exclusive License for Novel Molecules + Acquired an exclusive, perpetual license from Diverse Biotech, for 5 molecules, 4 of which are dermatology-focused and one that is pain- focused + Gain access to scientists and formulators to help with the res
Slide 23: MagicMed Industries — Psychedelics for CNS
MagicMed Industries — Psychedelics for CNS ¢ Intend to acquire 100% of MagicMed to expand access into Psychedelics and build on Neuroscience and CNS Conditions ¢ Molecule Agnostic Model to explore multiple ways to improve care M * Q 4 TC M ©O « Psybrary of 400+ Synthesized Compounds * 15 Patent Appl
Slide 24: World Class Institutional Partnerships
World Class Institutional Partnerships Developed partnerships with leading global institutions for WORLD CLASS INSTITUTIONS researching, developing and commercializing its naturally and Oncologists to Partner and Advise occurring compounds. SH St. George’s, University of London clea + Research capab
Slide 25: Projected Catalysts Going Forward
Projected Catalysts Going Forward Preparation: GMP Formulation Preclinical Validation Projected Events Radiation Dermatitis — US FDA IND Filing Glioblastoma Multiforme — Israeli MOH Study Authorization Radiation Dermatitis — Initiate Phase I/II Trial Glioblastoma Multiforme — Initiate Phase I/II Tri
Slide 26: Cannabinoid Industry Comps
Cannabinoid Industry Comps THE WALL STREET JOURNAL. BUSINESS Jazz Pharmaceuticals to Buy Cannabis-Based Drugmaker GW Pharma for $6.7 Billion Jazz bets drugs derived from the marijuana plant will be big players in treating neuroscience conditions NAME | TARGET | STAGE | MARKET CAP* Cara Therapeutics
Slide 27: Investment Highlights
Investment Highlights We are a patient-centric biotechnology company No Debt Strong Liquidity 18 Month Runway Undervalued vs NASDAQ Peers? Entering Clinical Stage PTSD Cancer WWW.ENVERIC.COM + NASDAQ: ENVB 1 7 Molecules Short & Long Term 1 Naturally Occurring Multiple Ways to Win 27
Slide 28: Thank You For Your Time
? in | SN Fe Bela@es C | E N\.@iEes THANK YOU FOR-YOUR TIME (NASDAQ: ENVB) JUNE 2021 WWW.ENVERIC.COM <
Enveric Biosciences — Merger or Acquisition (June 2021) on 6ix